Volume : 13, Issue : 06, June – 2026
Title:
METHOD DEVELOPMENT AND VALIDATION OF ASPIRIN IN PHARMACEUTICAL DOSAGE FORM BY UV VISIBLE SPECTROPHOTOMETRIC METHOD
Authors :
Mrs. G. Bhavani* P. Varalaxmi, T. Sushma sree, D. Susdharshan, K. Ravi kumar, Dr.T. Mangilal
Abstract :
Aspirin acts mainly by irreversibly inhibiting cyclooxygenase (COX) enzymes COX-1 and COX-2. This blocks the formation of prostaglandins and thromboxanes from arachidonic acid. The present study aimed to develop and validate a simple, rapid, accurate, and economical UV spectrophotometric method for the estimation of Aspirin in bulk drug form. Aspirin was dissolved in methanol and suitably diluted with distilled water to obtain the required concentrations. Methanol was used as the blank during analysis. For wavelength selection, a 10 µg/mL Aspirin solution was scanned, and the maximum absorbance (λmax) was observed at 295 nm. The developed method obeyed Beer–Lambert’s law over a concentration range of 5–25µg/mL. Method validation was performed according to pharmaceutical regulatory guidelines, evaluating parameters such as linearity, accuracy, precision, sensitivity, limit of detection (LOD), and limit of quantification (LOQ). The calibration curve showed good linearity with a regression coefficient (R²) of 0.9992. Accuracy was assessed through recovery studies, with percentage recoveries ranging from 98.32% to 100.8%. Precision studies demonstrated satisfactory reproducibility, with %RSD values less than 2%. The method exhibited good sensitivity, with LOD and LOQ values of 1µg/mL and 3.09 µg/mL, respectively. Overall, the validation results confirmed that the developed UV spectrophotometric method is accurate, precise, sensitive, and cost-effective for the routine estimation of Aspirin in bulk drug samples. Therefore, the method can be successfully employed in quality control laboratories for regular analysis of Aspirin.
Cite This Article:
Please cite this article in press G. Bhavani et al., Method Development And Validation Of Aspirin In Pharmaceutical Dosage Form By Uv Visible Spectrophotometric Method, Indo Am. J. P. Sci, 2026; 13(06).
REFERENCES:
1.Paez Espinosa EV, Murad JP, Khasawneh FT. Aspirin: Pharmacology and Clinical Applications. ISRN Pharmacology. 2012;2012:173124.
PMC
2.Werz O, Stettler H, Theurer C, Seibel J. The 125th Anniversary of Aspirin—The Story Continues. Pharmaceuticals. 2024;17(4):437.
MDPI
3.Fuster V, Sweeny JM. Aspirin: A Historical and Contemporary Therapeutic Overview. Circulation. 2011;123(7):768–778.
Icahn School of Medicine at Mount Sinai +1
4.Patrono C, Rocca B. Aspirin, 110 years later. Journal of Thrombosis and Haemostasis. 2009;7(Suppl 1):258–261.
PubMed
5.Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots—A concise summary. Vascular Pharmacology. 2019;113:1–8.
PubMed
6.Ugurlucan M, Caglar IM, Caglar FNT, et al. Aspirin: From a historical perspective. Current Drug Targets. 2012;7(1):71–76.
PubMed
7.Lévesque H, Lafont O. Aspirin throughout the ages: A historical review. Revue de Médecine Interne. 2000;21(Suppl 1):8S–17S.
PubMed
8.Gaglia MA Jr, Clavijo L. Cardiovascular Pharmacology Core Reviews: Aspirin. Vascular Medicine. 2013.
Sage Journals
9.Andermann AAJ. Physicians, Fads, and Pharmaceuticals: A History of Aspirin. McGill Journal of Medicine. 2020. �
mjm.mcgill.ca
10.Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.
11.Roth GJ, Majerus PW. The mechanism of action of aspirin on platelets.
12.Patrono C. Aspirin as an antiplatelet drug.
13.Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of antiplatelet therapy.
14.Awtry EH, Loscalzo J. Aspirin. Circulation. 2000.
15.Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for prevention of atherothrombosis.
16.Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease.
17.Gaziano JM. Aspirin for primary prevention of cardiovascular events.
18.Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in women.
19.McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in healthy elderly persons.
20.Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on long-term risk of cancer.
21.Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long-term aspirin use.
22.Yeomans ND. Aspirin and gastrointestinal injury.
23.Cryer B. Mechanisms of NSAID-induced gastrointestinal injury.
24.Patrono C, Baigent C. Role of aspirin in cardiovascular prevention.
25.Capodanno D, Angiolillo DJ. Aspirin for primary cardiovascular risk prevention.
26.De Berardis G, Sacco M, Strippoli GFM, et al. Aspirin for primary prevention in diabetes.
27.García Rodríguez LA, Martín-Pérez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding risk with long-term aspirin use.
28.Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction.
29.ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase and oral aspirin in acute myocardial infarction.
30.Patrono C, Rocca B. Aspirin and platelet inhibition in cardiovascular disease.